Testimony Before the FDA’s Arthritis Advisory Committee Regarding Baricitinib

View PDF: Summary | Presentation

In testimony before a meeting of the Food and Drug Administration’s (FDA’s) Arthritis Advisory Committee, Public Citizen urged the committee to recommend that the FDA reject Eli Lilly and Company’s new drug application for baricitinib for treatment of rheumatoid arthritis because it lacks any unique benefit over the very similar FDA-approved drug tofacitinib but causes unique life-threatening harms.